Us Fda Granted Orphan Drug Designation For Benlysta
Gsk Announced That The Us Food And Drug Administration (Fda) Has Granted Orphan Drug Designation (Odd) To Benlysta (Belimumab), A B-Cell Inhibiting Monoclonal Antibody, For The Potential Treatment Of Systemic Sclerosis. Gsk Plans To Initiate A Phase Ii/Iii Trial Of Belimumab For Systemic Sclerosis Associated Interstitial Lung Disease (Ssc-Ild) In The First Half Of 2023.With Limited Treatment Options Available For Ssc-Ild, The Orphan Drug Designation Reflects The Need For Further Research And The Potential For Belimumab To Address A Critical Need For People Living With This Debilitating Condition.The Us Fda
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
